PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Triptorelin

Drugs in development · updated 30 October 2026

Triptorelin: clinical trials and development status

Other names and codes: Decapeptyl, Triptodur Kit, Trelstar

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Triptorelin is in 24 active clinical trials (recruiting or ongoing, phases I–III) for 12 diseases. The most advanced phase is III.

24Active trials
IIIMost advanced phase
12Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Triptorelin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Prostatic NeoplasmsIII14NCT03678025
EndometriosisIII1NCT06525155
Ewing sarcomaIII1NCT05328258
InfertilityIII1NCT04064840
LymphomaIII1NCT05328258
MetastasisII–III1NCT04787744
OsteosarcomaIII1NCT05328258
SarcomaIII1NCT05328258
Breast neoplasmII1NCT05982093
Endometrial neoplasmII1NCT05247268
NeoplasmII1NCT05557604
Postmenopausal osteoporosisII1NCT07254429

Everything on Triptorelin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch